IgAN
European Renal Association (ERA) 2020
Virtual
June 6-9, 2020
Abstract
The 24-Week Interim Analysis Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
Barratt J, et al.